SQY Therapeutics

SQY Therapeutics is a technology platform that designs, develops, and produces a family of antisense oligonucleotide molecules to correct certain mutations through the "exon skipping" method. Currently, the company is developing several molecules for the treatment of Duchenne muscular dystrophy as well as other disease treatments in collaboration with or in partnership with others.